belimumab
Sign in to saveBelimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
Key facts
- Drug.O
- 2010
- Drug.S
- 44
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458612180
- Drug.type
- mab
- Drug.image
- Belimumab 5Y9K.png
- Drug.caption
- Fab fragment of belimumab. .
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- B-cell activating factor (BAFF, BLyS)
- Drug.tradename
- Benlysta
- Drug.MedlinePlus
- a611027
- Drug.DailyMedID
- Belimumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous, subcutaneous
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AG04
via Wikipedia infobox
Article
9 sectionsContents
- Medical uses
- Side effects and interactions
- Mechanism of action
- History
- Society and culture
- Legal status
- Economics
- Research
- References
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.
The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).